Cyclic Amide-Linked Oxazolidinone Triazoles as Inhibitors of the T-Box Riboswitch.

ABSTRACT: Antimicrobial resistance remains a critical global health challenge, and was intensified by the COVID-19 pandemic. To address this growing threat, novel antibacterial agents targeting unconventional mechanisms are urgently needed. One promising strategy involves inhibiting bacterial riboswitches-RNA elements that regulate gene expression. Unlike most riboswitches that respond to small-molecule metabolites, the T-box riboswitch uniquely binds non-aminoacylated tRNA and is predominantly found in Gram-positive bacteria, making it an attractive target due to its conserved sequences and regulatory role over essential genes. This study explored oxazolidinone- and triazole-based compounds as potential inhibitors of the T-box riboswitch. Prior investigations into tricyclic oxazolidinones revealed

SUBMITTER: Parsons E 

PROVIDER: S-EPMC12786550 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature